WO2000012047A3 - Enhancement of return to independent living status with a growth hormone secretagogue - Google Patents

Enhancement of return to independent living status with a growth hormone secretagogue Download PDF

Info

Publication number
WO2000012047A3
WO2000012047A3 PCT/US1999/019996 US9919996W WO0012047A3 WO 2000012047 A3 WO2000012047 A3 WO 2000012047A3 US 9919996 W US9919996 W US 9919996W WO 0012047 A3 WO0012047 A3 WO 0012047A3
Authority
WO
WIPO (PCT)
Prior art keywords
return
growth hormone
enhancement
hormone secretagogue
independent living
Prior art date
Application number
PCT/US1999/019996
Other languages
French (fr)
Other versions
WO2000012047A2 (en
Inventor
Mark Bach
Vivian Fuh
Jennifer Ng
Alice Taylor
Original Assignee
Merck & Co Inc
Mark Bach
Vivian Fuh
Jennifer Ng
Alice Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9823090.7A external-priority patent/GB9823090D0/en
Application filed by Merck & Co Inc, Mark Bach, Vivian Fuh, Jennifer Ng, Alice Taylor filed Critical Merck & Co Inc
Priority to CA002341649A priority Critical patent/CA2341649A1/en
Priority to JP2000571019A priority patent/JP2002525274A/en
Priority to EP99948091A priority patent/EP1156808A2/en
Priority to AU61332/99A priority patent/AU6133299A/en
Publication of WO2000012047A2 publication Critical patent/WO2000012047A2/en
Publication of WO2000012047A3 publication Critical patent/WO2000012047A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

A growth hormone secretagogue is useful for enhancing the return of patients to independent living status following acute deconditioning such as that which may result from immobilization, surgery, or major injury such as hip fracture.
PCT/US1999/019996 1998-09-02 1999-08-31 Enhancement of return to independent living status with a growth hormone secretagogue WO2000012047A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002341649A CA2341649A1 (en) 1998-09-02 1999-08-31 Enhancement of return to independent living status with a growth hormone secretagogue
JP2000571019A JP2002525274A (en) 1998-09-02 1999-08-31 Promotion of return to independent living condition by growth hormone secretagogue
EP99948091A EP1156808A2 (en) 1998-09-02 1999-08-31 Enhancement of return to independent living status with a growth hormone secretagogue
AU61332/99A AU6133299A (en) 1998-09-02 1999-08-31 Enhancement of return to independent living status with a growth hormone secretagogue

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9886998P 1998-09-02 1998-09-02
US60/098,869 1998-09-02
GBGB9823090.7A GB9823090D0 (en) 1998-10-21 1998-10-21 Enhancement of return to independent living status with a growth hormone secretaogue
GB9823090.7 1998-10-21

Publications (2)

Publication Number Publication Date
WO2000012047A2 WO2000012047A2 (en) 2000-03-09
WO2000012047A3 true WO2000012047A3 (en) 2001-09-27

Family

ID=26314549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019996 WO2000012047A2 (en) 1998-09-02 1999-08-31 Enhancement of return to independent living status with a growth hormone secretagogue

Country Status (5)

Country Link
EP (1) EP1156808A2 (en)
JP (1) JP2002525274A (en)
AU (1) AU6133299A (en)
CA (1) CA2341649A1 (en)
WO (1) WO2000012047A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
EP1192943A3 (en) * 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
CU23157A1 (en) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TISSULAR DANE DUE TO LACK OF BLOOD IRRIGATION ARTERIAL
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087069A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
JP5336349B2 (en) * 2006-03-15 2013-11-06 マイケル・オー・ソーナー Method for treating sarcopenia with growth hormone secretagogue

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (en) * 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO1997024369A1 (en) * 1995-12-28 1997-07-10 Pfizer Inc. Growth-hormone secretagogues
US5723616A (en) * 1995-10-27 1998-03-03 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
US5773441A (en) * 1995-08-21 1998-06-30 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773441A (en) * 1995-08-21 1998-06-30 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
US5723616A (en) * 1995-10-27 1998-03-03 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
WO1997021730A1 (en) * 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO1997024369A1 (en) * 1995-12-28 1997-07-10 Pfizer Inc. Growth-hormone secretagogues

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 10 July 1997 (1997-07-10), CARPINO P.A. ET AL.: "Preparation of Nitrogen Heterocyclic Peptide Analogs as Growth-Hormone Secretagogues" *
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 19 June 1997 (1997-06-19), ARENA J.P. ET AL.: "Growth Hormone Secretagogue Receptor Family and Their cDNA Sequences from Human, Swine and Rat" *
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 1997, LIEBER R.L. ET AL.: "Growth Hormone Secretagogue Increases Muscle Strength During Remobilization After Canine Hindlimb Immobilization" *
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 1998, MURPHY M.G. ET AL.: "MK-677, An Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism" *
J. CLIN. ENDOCRINOL. METAB.,, vol. 83, no. 2, 1998, pages 320 - 325 *
J. ORTHOP. RES.,, vol. 15, no. 4, 1997, pages 519 - 527 *

Also Published As

Publication number Publication date
JP2002525274A (en) 2002-08-13
AU6133299A (en) 2000-03-21
CA2341649A1 (en) 2000-03-09
WO2000012047A2 (en) 2000-03-09
EP1156808A2 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
NO924697D0 (en) SURGICAL IMPLANT AND A PROCEDURE FOR TREATMENT OF SURGICAL IMPLANT
EP1121904A3 (en) Fixation member for treating orthopaedic fractures
ZA9711353B (en) Intramedullary cavity nail for the treatment of fractures of the hip.
ZA964816B (en) Implant for the surgical treatment of a vertebral isthmus fracture.
ATE255367T1 (en) INTEGRAL NAIL SYSTEM FOR FRACTURE HEALING OR BONE LENGTHENING
ZA200204327B (en) Implantable screw for stabilization of a joint or a bone fracture.
DE50014411D1 (en) MEDICAL INSTRUMENT FOR THE DISPOSAL OF TISSUE, BONE CEMENT OR THE SIMILAR IN THE HUMAN OR ANIMAL BODY
DE59810425D1 (en) MARBLE NAIL FOR OPERATING TREATMENT OF FOREARM FRACTURES
NO2014010I2 (en)
AU2154700A (en) Systems for securing sutures, grafts and soft tissue to bone and periosteum
WO2004032988A3 (en) Coupling agents for orthopedic biomaterials
AU2001258138A1 (en) Bone plate for the fixation of fractures of the proximal humerus
WO2003084602A3 (en) Device for stimulating bone growth, especially for the osteosynthesis of bone fragments and/or for fixing bone fractures
AU1977800A (en) Improved device for the external fixation of bones fractures, in particular ankle fractures
WO2004039236A3 (en) Bone plate assembly provided with screw locking mechanisms
FR2796545B1 (en) POLY-AXIAL LINK FOR OSTEOSYNTHESIS SYSTEM, ESPECIALLY FOR THE RACHIS
WO2002040069A3 (en) Bioactive surgical suture
WO2000012047A3 (en) Enhancement of return to independent living status with a growth hormone secretagogue
AU3904200A (en) Bone fracture fixation clip
EP0366029A3 (en) Bone repairing material and artificial bone fixing agent
WO2002096324A3 (en) Bone implant
WO2002005718A3 (en) Suture anchor for attaching a suture to a bone part
WO2003022224A3 (en) Cox-2 function and wound healing
SU1192799A1 (en) Method of plasty of the roof of cotyloid cavity
MD1268B2 (en) Method for surgical treatment of meta-physar fracture of children should bone distal part

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 61332/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2341649

Country of ref document: CA

Ref country code: CA

Ref document number: 2341649

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 571019

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999948091

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999948091

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999948091

Country of ref document: EP